🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

RecruitingPhase 1Ages 18 Years - anyAllTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Ther…
NCT06917079 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation * Measurable disease by RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 * Life expectancy \>24 weeks * Adequate organ function Exclusion Criteria: * Malignancy within the last 2 years as specified in the protocol * Untreated brain metastases Other inclusion/exclusion criteria are specified in the protocol.
💊

What it tests

  • BBO-11818
  • Pembrolizumab
  • Platinum chemotherapy (cisplatin or carboplatin)
  • Pemetrexed
  • Cetuximab
📍

Where

17 sites
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, United States
University of California Davis
Sacramento, United States
University of California San Diego Moores Cancer Center
San Diego, United States
University of California San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, United States
Yale University
New Haven, United States
Moffitt Cancer Center
Tampa, United States
OSF Healthcare Cancer Institute
Peoria, United States
Massachusetts General Hospital
Boston, United States

…and 9 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy